期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 59, 期 42, 页码 18755-18762出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202008624
关键词
anticancer; epigenetics; drug discovery; metabolism; rhenium
资金
- National Natural Science Foundation of China [21778078, 91953117, 21837006]
- innovative team of Ministry of Education [IRT_17R111]
- Guangdong Natural Science Foundation [2015A030306023]
- Fundamental Research Funds for the Central Universities
The development and malignancy of cancer cells are closely related to the changes of the epigenome. In this work, a mitochondria-targeted rhenium(I) complex (DFX-Re3), integrating the clinical iron chelating agent deferasirox (DFX), has been designed. By relocating iron to the mitochondria and changing the key metabolic species related to epigenetic modifications,DFX-Re3can elevate the methylation levels of histone, DNA, and RNA. As a consequence,DFX-Re3affects the events related to apoptosis, RNA polymerases, and T-cell receptor signaling pathways. Finally, it is shown thatDFX-Re3induces immunogenic apoptotic cell death and exhibits potent antitumor activity in vivo. This study provides a new approach for the design of novel epigenetic drugs that can recode the cancer epigenome by intervening in mitochondrial metabolism and iron homeostasis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据